Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases. Source
No articles found.
Today's adults juggle caring for aging parents and children while working full-tim...
Today's adults juggle caring for aging parents ...
Natera is a rapidly-growing diagnostics company with proprietary bioinformatics an...
Natera is a rapidly-growing diagnostics company...
Life gets in the way of eating right. With a quick assessment of your lifestyle, N...
Life gets in the way of eating right. With a qu...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company develop...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stag...
Neos Therapeutics develops, manufactures, and commercializes innovative extended-r...
Neos Therapeutics develops, manufactures, and c...
Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metab...
Simulations Plus, Inc. is the leading developer...
Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...
Seres Therapeutics, Inc. is a microbiome therap...
Join the National Investor Network and get the latest information with your interests in mind.